The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
Nicole M Gerlanc,1 Jennifer Cai,2 Joseph Tkacz,1 Susan C Bolge,2 Brenna L Brady1 1Health Analytics, LLC Columbia, MD, USA; 2Janssen Scientific Affairs, LLC Titusville, NJ, USA Objective: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used...
Guardado en:
Autores principales: | Gerlanc NM, Cai J, Tkacz J, Bolge SC, Brady BL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/43fc34719f7245eb8bfe5006f4af0d0b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effect of weight loss on adipokine levels in obese patients
por: Hession M, et al.
Publicado: (2011) -
Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies MJ, et al.
Publicado: (2017) -
Predictors of weight loss and maintenance in patients treated with antiobesity drugs
por: Guaraldi F, et al.
Publicado: (2011) -
Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019) -
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming JW, et al.
Publicado: (2015)